Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human menopausal gonadotropin-induced bioprosthetic valve thrombosis.

ABSTRACT: Bioprosthetic valve thrombosis (BPVT) is a rare but potentially life-threatening complication. Human menopausal gonadotropin (hMG) is commonly used for ovulation induction and has been associated with arterial and venous thrombosis. We reported a case of BPVT related to in vitro fertilization in a 39-year-old female, who underwent redo mitral valve replacement. To the best of our knowledge, this is the first case of hMG-induced BPVT in a young female patient.

SUBMITTER: Abazid RM

PROVIDER: S-EPMC6057167 | biostudies-literature | 2018 Jul-Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Human menopausal gonadotropin-induced bioprosthetic valve thrombosis.

Abazid Rami Mahmood RM Shoman Mohamed M Smettie Osama A OA Elamin Osama A OA

Avicenna journal of medicine 20180701 3

Bioprosthetic valve thrombosis (BPVT) is a rare but potentially life-threatening complication. Human menopausal gonadotropin (hMG) is commonly used for ovulation induction and has been associated with arterial and venous thrombosis. We reported a case of BPVT related to <i>in vitro</i> fertilization in a 39-year-old female, who underwent redo mitral valve replacement. To the best of our knowledge, this is the first case of hMG-induced BPVT in a young female patient. ...[more]

PMID: 30090752

Similar Datasets

Recurrent bioprosthetic mitral valve thrombosis treated with anticoagulation.

Project description:Bioprosthetic valve thrombosis (BPVT) is more common than previously thought and likely underreported. BPVT can be accurately diagnosed with cardiac imaging and treated successfully with anticoagulation, thus preventing reoperation. We hereby report a case of recurrent BPVT in the mitral position successfully treated with anticoagulation along with review of literature.

| S-EPMC8749813 | biostudies-literature

Intracardiac Echocardiography to Diagnose Bioprosthetic Pulmonary Valve Thrombosis.

Project description:A 48-year-old woman presented with heart failure and bioprosthetic pulmonary valve regurgitation 2 years after pulmonary valve replacement. Intracardiac echocardiography demonstrated uniform thickening of a single prosthetic valve leaflet suggesting leaflet thrombosis rather than bioprosthetic valve degeneration. After 3 months of anticoagulation, valve regurgitation and symptoms improved. (Level of Difficulty: Intermediate.).

| S-EPMC8302786 | biostudies-literature

Bioprosthetic Valve Thrombosis and Obstruction Secondary to COVID-19.

Project description:Patients with COVID-19 may present a hypercoagulable state, with an important impact on morbidity and mortality. Because of this situation pulmonary embolism is a frequent complication during the course of infection. We present the case of a patient recently discharged, after admission with confirmed COVID-19, who developed a pulmonary embolism and thrombosis of a biological mitral valve prosthesis, producing valve obstruction and stenosis. After 15 days of anticoagulant treatment, resolution of the thrombus and normalisation of prosthetic valve function was observed. This case supports current recommendations of administering full-dose anticoagulation therapy to COVID-19 patients with biological heart valve prosthesis, even after the acute phase of infection.

| S-EPMC7585166 | biostudies-literature

A Case of Bioprosthetic Mitral Valve Dysfunction, Initially Presenting with Valve Thrombosis Followed by Recurrent Thrombosis and Endocarditis.

Project description:Highlights•Bioprosthetic valve thrombosis (BPVT) can occur beyond 3 months postimplantation.•BPVT can reoccur after successful treatment with fibrinolysis and anticoagulation.•Other forms of bioprosthetic valve dysfunction can coexist with thrombosis.•Echocardiography can promptly diagnose bioprosthesis thrombosis.•Management requires valve replacement, thrombolysis, or anticoagulation•After BPVT long-term anticoagulation may be required.

| S-EPMC6833127 | biostudies-other

Reversal of Bioprosthetic Aortic Valve Thrombosis Using Rivaroxaban-A Case Report.

Project description:Background: Bioprosthetic valve thrombosis (BPVT) is a rare but recognized complication causing valve dysfunction. In subacute valve thrombosis, systemic oral anticoagulation is recommended. However, there is little data comparing the efficacy of warfarin and novel oral anticoagulant (NOAC) therapy in this setting. Case Summary: A patient developed subacute BPVT 11 years post-implantation. The patient was initially treated with warfarin for a period of 6 months, with limited effect. Following replacement of warfarin with rivaroxaban, there was significant reversal of the BPVT, as represented by a reduction in transaortic maximal velocity (Vmax) from 4.1 to 3 m/s over 7 months. Discussion: Systemic oral anticoagulation can be an effective treatment for subacute valve thrombosis. Guidelines currently recommend warfarin as first line but NOACs can be considered in such patients and may be more effective than warfarin. Randomized controlled trials are required to further establish the optimal anticoagulation for patients with subacute BPVT.

| S-EPMC7266867 | biostudies-literature

Thrombolysis for COVID-19-associated bioprosthetic mitral valve thrombosis with shock.

Project description: Not available

| S-EPMC8344413 | biostudies-literature

Emergent Surgical Replacement of a Tendyne Prosthesis for Bioprosthetic Valve Thrombosis.

Project description:A 66-year-old woman with a complex medical history underwent transcatheter mitral valve replacement (TMVI) owing to mitral insufficiency. Risk factors and noncompliance led to bioprosthetic valve thrombosis (BPVT) within 3 years. Emergent surgery indicated by an ad hoc heart team successfully managed the situation, showcasing challenges in BPVT management after TMVI.

| S-EPMC11328740 | biostudies-literature

Bioprosthetic Valve Thrombosis while on a Novel Oral Anticoagulant for Atrial Fibrillation.

Project description: Not available

| S-EPMC6058412 | biostudies-literature

Impact of leaflet thrombosis on hemodynamics and clinical outcomes after bioprosthetic aortic valve replacement: A meta-analysis.

Project description:BackgroundLeaflet thrombosis (LT, also called cusp thrombosis) detected by multidetector computed tomography (MDCT) is common in bioprosthetic aortic valve replacement (bAVR). However, it remains contradictory whether MDCT-defined LT following bAVR is associated with hemodynamic deterioration and stroke. Thus, we performed the first meta-analysis to assess hemodynamic outcomes and updated the latest researches on the clinical outcomes of MDCT-defined LT after bAVR.HypothesisMDCT-defined LT might be associated with worse hemodynamic and clinical outcomes after bAVR.MethodMEDLINE, EMBASE, Cochrane Library, and ClinicalTrial.gov were searched from inception to 15th April 2019. The fix-effect model was utilized to calculate odds ratio (OR) and 95% confidence interval (CI). The primary outcomes were hemodynamic stability indexes, including mean pressure gradient (MPG), left ventricular ejection fraction (LVEF), paravalvular leak (PVL), and clinical heart failure. The secondary endpoints were major adverse cardiovascular and cerebrovascular events (MACCEs), which consisted of myocardial infarction, all-cause death, stroke, and transient ischemic attack (TIA).ResultsTwelve studies with 4820 patients were included. The total prevalence of MDCT-defined LT was 9.7%. MDCT-defined LT was associated with a significantly increased risk of MPG (inverse variance 0.43, 95% CI: [0.30, 0.57]), MACCEs (OR 2.43, 95% CI: [1.45, 4.06]), stroke (OR 1.79, 95% CI: [1.03, 3.11]), and TIA (OR 4.09, 95% CI: [1.59, 10.54]). There were no differences for other outcomes.ConclusionsMDCT-defined LT after bAVR is associated with increased MPG and increased risk of adverse cerebrovascular events, including TIA and stroke. While LVEF, PVL, and clinical heart failure were similar between patient with and without LT.

| S-EPMC7244303 | biostudies-literature

Transcatheter tricuspid valve-in-valve implantation in a dysfunctional bioprosthetic valve.

Project description: Not available

| S-EPMC8167470 | biostudies-literature